Keyphrases
Pancreatic Ductal Adenocarcinoma
100%
Immune Checkpoint Inhibitors
100%
Programmed Death-ligand 1 (PD-L1)
25%
Cancer Cells
25%
Immune-privileged
25%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
25%
Recent Advances
12%
Therapeutic Potential
12%
In Cancer
12%
Cancer Treatment
12%
Tumor Subtype
12%
Malignant Cells
12%
Hematological Malignancies
12%
Tumor Microenvironment
12%
Preneoplastic
12%
Immune Escape
12%
Immunotherapeutics
12%
Immunogenicity
12%
Overall Survival
12%
Solid Tumors
12%
Targeted Therapy
12%
Antigenicity
12%
Pancreatic Malignancy
12%
Anti-cytotoxic
12%
Intrinsic Mechanism
12%
Dismal Prognosis
12%
Emerging Therapeutics
12%
Tumor Heterogeneity
12%
Anti-programmed Cell Death Protein 1
12%
Antitumor Immune Response
12%
Immunosuppressive Microenvironment
12%
Cell-intrinsic
12%
Biochemistry, Genetics and Molecular Biology
Immune Checkpoints
100%
Immunity
75%
Cancer Cell
50%
CTLA-4
50%
Immune Response
25%
Overall Survival
25%
Cell Death
25%
Synapsin I
25%
Immunogenicity
25%
Antigenicity
25%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
100%
Malignant Neoplasm
50%
Immune Checkpoint Inhibitor
25%
Tumor Microenvironment
25%
Cytotoxic T Lymphocyte Antigen 4
25%
Immunogenicity
12%
Solid Malignant Neoplasm
12%
Overall Survival
12%
Immunosuppressive Agent
12%
Hematologic Malignancy
12%
Programmed Death 1 Receptor
12%
Neoplasm
12%
Immunology and Microbiology
Immunity
100%
Cancer Cell
33%
CTLA-4
33%
Immune Escape
16%
Immunogenicity
16%
Immunosuppressive Drug
16%
Antigenicity
16%
Immune Response
16%
Overall Survival
16%
Programmed Death 1 Receptor
16%